BMS-986120

BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC50s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects[1][2].

Product Specifications

CAS Number

[1478712-37-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/BMS-986120.html

Purity

98.22

Solubility

DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

CC(SC(N1CCOCC1)=N2)=C2COC3=CC(OC)=CC4=C3C=C(O4)C5=CN6N=C(OC)SC6=N5

Molecular Formula

C23H23N5O5S2

Molecular Weight

513.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Pancras C Wong, et al. Abstract 175: A Novel Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986120, Inhibits Arterial Thrombosis With Limited Impact on Hemostasis in Cynomolgus Monkeys. Stroke. 2018;47:A175.|[2]Wilson SJ, et al. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex VivoThrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38 (2) :448-456.|[3]Wong PC, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med. 2017 Jan 4;9 (371) .